Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
AssigneeSchering Corporation
InventorsTimothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Kartik M. Keertikar
Life of this patent
Estimating the term…
Abstract
In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. All illustrative compound is shown below:
Claims14
A compound selected from the group consisting of the compounds of the formula:
- or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.